CDER pregnancy labeling (correction)
FDA's pregnancy labeling initiative will remain under the Office of New Drugs following a reorganization that will create an Office of Counterterrorism & Pediatric Drug Development (formerly Office of Pediatric Drug Development & Program Initiatives) under the office of the CDER director. "The Pink Sheet" (July 1, p. 18) incorrectly referred to the pregnancy labeling initiative as a "pediatric" initiative...
You may also be interested in...
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”